PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16927149-0	2006	Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease.	Rabeprazole	44-55	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-27	
14664653-9	2003	However, there are significant genetic polymorphisms for one of the cytochrome P450 (CYP) isoenzymes involved in PPI metabolism (CYP2C19), and this polymorphism has been shown to substantially increase plasma levels of omeprazole, lansoprazole and pantoprazole, but not those of rabeprazole.	Rabeprazole	279-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83	
14664653-9	2003	However, there are significant genetic polymorphisms for one of the cytochrome P450 (CYP) isoenzymes involved in PPI metabolism (CYP2C19), and this polymorphism has been shown to substantially increase plasma levels of omeprazole, lansoprazole and pantoprazole, but not those of rabeprazole.	Rabeprazole	279-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-88	
12495367-12	2002	The hepatic metabolism of rabeprazole is predominantly by nonenzymatic reactions and minimally by CYP-mediated reactions, which therefore confers an advantage over older PPIs in that genetic polymorphisms for CYP2C19 do not significantly influence rabeprazole clearance, clinical efficacy or potential for drug interactions.	Rabeprazole	26-37	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-101	
10491726-0	1999	Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.	Rabeprazole	90-101	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-31	
11430508-4	2001	Rabeprazole and esomeprazole achieve more rapid and profound inhibition of acid secretion than do older agents, and they sustain this suppression to provide acid control and symptom relief over 24 h. The balanced hepatic metabolism of rabeprazole, involving both cytochrome P450 (CYP)-mediated reactions in the liver and nonenzymatic reactions, appears to confer an advantage over older PPIs in that genetic polymorphisms for CYP 2C19 do not significantly influence rabeprazole clearance and, potentially, clinical efficacy.	Rabeprazole	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	263-278	
11430508-4	2001	Rabeprazole and esomeprazole achieve more rapid and profound inhibition of acid secretion than do older agents, and they sustain this suppression to provide acid control and symptom relief over 24 h. The balanced hepatic metabolism of rabeprazole, involving both cytochrome P450 (CYP)-mediated reactions in the liver and nonenzymatic reactions, appears to confer an advantage over older PPIs in that genetic polymorphisms for CYP 2C19 do not significantly influence rabeprazole clearance and, potentially, clinical efficacy.	Rabeprazole	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	280-283	
11430508-4	2001	Rabeprazole and esomeprazole achieve more rapid and profound inhibition of acid secretion than do older agents, and they sustain this suppression to provide acid control and symptom relief over 24 h. The balanced hepatic metabolism of rabeprazole, involving both cytochrome P450 (CYP)-mediated reactions in the liver and nonenzymatic reactions, appears to confer an advantage over older PPIs in that genetic polymorphisms for CYP 2C19 do not significantly influence rabeprazole clearance and, potentially, clinical efficacy.	Rabeprazole	235-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	263-278	
11430508-4	2001	Rabeprazole and esomeprazole achieve more rapid and profound inhibition of acid secretion than do older agents, and they sustain this suppression to provide acid control and symptom relief over 24 h. The balanced hepatic metabolism of rabeprazole, involving both cytochrome P450 (CYP)-mediated reactions in the liver and nonenzymatic reactions, appears to confer an advantage over older PPIs in that genetic polymorphisms for CYP 2C19 do not significantly influence rabeprazole clearance and, potentially, clinical efficacy.	Rabeprazole	235-246	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	280-283